(MedPage Today) — BERLIN — For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall survival (OS) in high-risk early breast cancer, data reported here showed.
Patients who received…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118016
Author :
Publish date : 2025-10-18 17:26:00
Copyright for syndicated content belongs to the linked Source.
